Your browser doesn't support javascript.
loading
Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC).
Rafii, H; Frère, C; Benzidia, I; Crichi, B; Andre, T; Assenat, E; Bournet, B; Carpentier, A; Connault, J; Doucet, L; Durant, C; Emmerich, J; Gris, J C; Hij, A; Le Hello, C; Madelaine, I; Messas, E; Ndour, A; Villiers, S; Marjanovic, Z; Ait Abdallah, N; Yannoutsos, A; Farge, D.
Affiliation
  • Rafii H; Eurocord, Équipe 3 EA3518, hôpital Saint-Louis, Université de Paris, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: hanadi.rafii-elayoubi@aphp.fr.
  • Frère C; Inserm UMRS_1166, Department of Haematology, hôpital Pitié-Salpêtrière, Université de Paris, Sorbonne Paris-Cité, AP-HP, Paris, France.
  • Benzidia I; Autoimmune and vascular disease unit, hôpital Saint-Louis, Internal Medicine (UF04), Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, EA3518, AP-HP, Sorbonne Paris-Cité, Paris, France.
  • Crichi B; Autoimmune and vascular disease unit, hôpital Saint-Louis, Internal Medicine (UF04), Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, EA3518, AP-HP, Sorbonne Paris-Cité, Paris, France.
  • Andre T; Hôpital Saint-Antoine, AP-HP, Paris, France.
  • Assenat E; Montpellier school of Medicine, Saint-Eloi University Hospital, Montpellier, France.
  • Bournet B; Hôpital Rangueil, CHU de Toulouse, Toulouse, France.
  • Carpentier A; Hôpital Saint-Louis, AP-HP, Paris, France.
  • Connault J; CHU de Nantes, Nantes, France.
  • Doucet L; Hôpital Saint-Louis, AP-HP, Paris, France.
  • Durant C; CHU de Nantes, Nantes, France.
  • Emmerich J; Saint-Joseph Hospital, Paris, France.
  • Gris JC; CHU de Nîmes, Nîmes, France.
  • Hij A; Autoimmune and vascular disease unit, hôpital Saint-Louis, Internal Medicine (UF04), Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, EA3518, AP-HP, Sorbonne Paris-Cité, Paris, France.
  • Le Hello C; CHU Saint-Étienne, Saint-Étienne, France.
  • Madelaine I; Hôpital Saint-Louis, AP-HP, Paris, France.
  • Messas E; Hôpital Européen Georges-Pompidou, AP-HP, Paris, France.
  • Ndour A; Hôpital Saint-Louis, AP-HP, Paris, France.
  • Villiers S; Hôpital Saint-Louis, AP-HP, Paris, France.
  • Marjanovic Z; Hôpital Saint-Antoine, AP-HP, Paris, France.
  • Ait Abdallah N; Autoimmune and vascular disease unit, hôpital Saint-Louis, Internal Medicine (UF04), Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, EA3518, AP-HP, Sorbonne Paris-Cité, Paris, France.
  • Yannoutsos A; Saint-Joseph Hospital, Paris, France.
  • Farge D; Internal Medicine (UF04), Équipe 3 EA 3518, Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Center of reference for rare systemic autoimmune diseases (FAI2R), Université de Paris, AP-HP, Sorbonne Paris-Cité, Paris, France; Department of Medicine, McGill University, Montreal, QC, Canada.
J Med Vasc ; 45(1): 28-40, 2020 Feb.
Article in En | MEDLINE | ID: mdl-32057323
ABSTRACT
Venous thromboembolism (VTE) is a common disease complication in cancer patients and the second cause of death after cancer progression. VTE management and prophylaxis are critical in cancer patients, but effective therapy can be challenging because these patients are at higher risk of VTE recurrence and bleeding under anticoagulant treatment. Numerous published studies report inconsistent implementation of existing evidence-based clinical practice guidelines (CPG), including underutilization of thromboprophylaxis, and wide variability in clinical practice patterns across different countries and various practitioners. This review aims to summarize the 2019 ITAC-CME evidence-based CPGs for treatment and prophylaxis of cancer-related VTE, which include recommendations on the use of direct oral anticoagulants specifically in cancer patients. The guidelines underscore the gravity of developing VTE in cancer and recommend the best approaches for treating and preventing cancer-associated VTE, while minimizing unnecessary or over-treatment. Greater adherence to the 2019 ITAC guidelines could substantially decrease the burden of VTE and improve survival of cancer patients.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Practice Guidelines as Topic / Venous Thromboembolism / Anticoagulants / Neoplasms Type of study: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Limits: Humans Language: En Journal: J Med Vasc Year: 2020 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Practice Guidelines as Topic / Venous Thromboembolism / Anticoagulants / Neoplasms Type of study: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Limits: Humans Language: En Journal: J Med Vasc Year: 2020 Document type: Article